Related Experiment Video
Updated: Jul 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Evaluation of nevirapine-switch strategies for HIV treatment
1Division of Infectious Diseases, University of Ottawa Hospital, The Ottawa Hospital-General Campus, 501 Smyth Road, Ottawa, Ontario, Canada. ccooper@ottawahospital.on.ca
Abstract:
Despite the benefits of protease inhibitor (PI)-based HIV treatment, issues of tolerability, dosing frequency, pill count and long-term metabolic complications necessitate evaluation of alternate treatment strategies. The weight of evidence demonstrates that a switch from a PI-based regimen to one containing nevirapine can be accomplished safely while maintaining virological suppression. There is no immunological cost. There is probably an overall benefit in terms of the metabolic milieu.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Pharmacokinetics in Pediatric Patients: Drug Excretion
Retroviruses
Subviral Agents
Inhibitors of Viral Protein Synthesis

